Detailed price information for Vera Therapeutics Inc Cl A (VERA-Q) from The Globe and Mail including charting and trades.

According to data from market research firm Pharmarack, the combined number of ARV and immunoglobulin vaccines sold in 2025 ...

FDA assigned PDUFA target action date of July 7, 2026.If approved, atacicept would be the first B cell modulator targeting ...

Zenas BioPharma ZBIO announced that the phase III INDIGO study, which evaluated its lead pipeline candidate, obexelimab, for ...

A live webcast of the presentation will be available in the “Investors” section of the SAB BIO website at www.sab.bio. An archived replay will be available on the Company’s website for approximately ...

Despite the magnitude of the decline, the structural setup suggests caution remains warranted. Zenas is still firmly within ...

As of Monday, January 05, Zenas BioPharma, Inc.’s ZBIO share price has dipped by 55.44%, which has investors questioning if ...

Zenas BioPharma shares fell sharply after the company reported favorable Phase 3 study results for obexelimab in immunoglobulin G4-related disease. The stock fell 56% to $15.22. Despite Monday's ...

Zenas BioPharma said on Monday its experimental drug cut the risk of flare-ups of a rare autoimmune disease in a late-stage study, but its shares fell 57% as the drug's efficacy fell short of ...

Zenas BioPharma (NASDAQ:ZBIO) shares plunged about 50% after the company released results from its Phase 3 INDIGO study ...

Zenas BioPharma shares fall after Phase 3 obexelimab data in IgG4-RD showed a 56% flare risk reduction, as investors weigh ...

Zenas BioPharma (ZBIO) stock plunges as the company posts late-stage trial data for its lead asset, obexelimab, in ...